Business
Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research
Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).Autism Study GraphicTo view an.
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).","length":473,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":826,"url":"https://media.zenfs.com/en/newsfile_64/bcb9ff70d2e1a370aa3b19603bf12ecb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QW8b3Yqey_SVA0t4_wCzog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NDI7Y2Y9d2VicA--/https://media.zenfs.com/en/newsfile_64/bcb9ff70d2e1a370aa3b19603bf12ecb","width":550,"height":826}},"href":"https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic.jpg","hrefExternal":true},{"type":"text","content":"Autism Study Graphic","length":20,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/282995_autism_study_graphic.jpg","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"The planned studies may be conducted directly at the Adia Med clinic in Winter Park, Florida, or in collaboration with partner clinics across the United States. To support this growth, Adia Med is actively in discussions with multiple clinics nationwide to secure Institutional Review Board (IRB) approvals and enable multi-site participation.","length":343,"tagName":"p"},{"type":"text","content":"Among the priority efforts already under discussion are:","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"An expansion of the current IRB-approved Autism Spectrum Disorder (ASD) study (ClinicalTrials.gov NCT07304440) to include 13-year-old children, extending eligibility beyond the existing 3-12 age range and allowing more families to access the innovative protocol combining Adia Vita with glutathione therapy.","length":307,"tagName":"p"}]},{"val":[{"type":"text","content":"The launch of a dedicated new study evaluating Adia Vita in ...